TD Cowen analyst Phil Nadeau has maintained their bullish stance on AURA stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Phil Nadeau has given his Buy rating due to a combination of factors that highlight Aura Biosciences Inc’s promising developments in their clinical trials. The company is advancing with bel-sar’s pivotal Phase III trial in choroidal melanoma, which has shown significant progress with approximately 240 patients pre-screened and ready for enrollment. This trial is expected to complete enrollment by the end of 2025, with results anticipated by mid-2027, indicating a strong pipeline for future growth.
Additionally, the initial data from bel-sar’s trial in bladder cancer has been promising, with notable clinical complete responses in patients with intermediate and high-risk non-muscle invasive bladder cancer (NMIBC). The ongoing Phase Ib/II trial is set to provide further efficacy data by the end of 2025 or early 2026. These developments, along with the company’s solid financial position with cash runway into the first half of 2027, support the Buy rating as they suggest potential for significant advancements and value creation in the near future.
Nadeau covers the Healthcare sector, focusing on stocks such as Kura Oncology, Syndax Pharmaceuticals, and Biogen. According to TipRanks, Nadeau has an average return of 2.7% and a 40.87% success rate on recommended stocks.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $23.00 price target.